Integrated BioPharma, Inc.
INBPOTCConsumer Defensive● Active
$0.18
+$0.00(+1.48%)
Market Cap$5696643
P/E Ratio—
52W High$0.42
52W Low$0.17
Integrated BioPharma, Inc. (INBP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INBP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.03
Revenue
$0.01B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
INBP reports quarterly as a OTC-listed Packaged Foods company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 8, 2026 | — | -$0.03 | — | $0.01B | — | — |
| — Q1 FY2026 | Feb 11, 2026 | — | -$0.03 | — | $0.01B | — | — |
| — Q4 FY2025 | Nov 10, 2025 | — | $0.00 | — | — | — | — |
| — Q3 FY2025 | Sep 23, 2025 | — | -$0.01 | — | $0.01B | — | — |
| — Q2 FY2025 | May 14, 2025 | — | $0.02 | — | $0.01B | — | — |
| — Q1 FY2025 | Feb 13, 2025 | — | $0.00 | — | $0.01B | — | — |
| — Q4 FY2024 | Nov 13, 2024 | — | $0.01 | — | $0.03B | — | — |
| — Q3 FY2024 | Sep 20, 2024 | — | $0.01 | — | $0.01B | — | — |
Q2 FY2026
May 8, 2026
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2026
Feb 11, 2026
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2025
Nov 10, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 23, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q2 FY2025
May 14, 2025
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Feb 13, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Nov 13, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q3 FY2024
Sep 20, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 8, 2026 | — | $0.25 | $0.25 | +0.00% |
| — Q1 FY2026 | Feb 11, 2026 | — | $0.32 | $0.30 | -6.25% |
| — Q4 FY2025 | Nov 10, 2025 | — | $0.31 | $0.31 | +0.32% |
| — Q3 FY2025 | Sep 23, 2025 | — | $0.28 | $0.33 | +17.86% |
| — Q2 FY2025 | May 14, 2025 | — | $0.26 | $0.29 | +11.27% |
| — Q1 FY2025 | Feb 13, 2025 | — | $0.31 | $0.26 | -15.48% |
| — Q4 FY2024 | Nov 13, 2024 | — | $0.31 | $0.32 | +3.23% |
| — Q3 FY2024 | Sep 20, 2024 | — | $0.23 | $0.23 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 8, 2026
EPS Beat/Miss
—
Price Before
$0.25
Price After
$0.25
Q1 FY2026-6.25%
Report Date
Feb 11, 2026
EPS Beat/Miss
—
Price Before
$0.32
Price After
$0.30
Q4 FY2025+0.32%
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$0.31
Price After
$0.31
Q3 FY2025+17.86%
Report Date
Sep 23, 2025
EPS Beat/Miss
—
Price Before
$0.28
Price After
$0.33
Q2 FY2025+11.27%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$0.26
Price After
$0.29
Q1 FY2025-15.48%
Report Date
Feb 13, 2025
EPS Beat/Miss
—
Price Before
$0.31
Price After
$0.26
Q4 FY2024+3.23%
Report Date
Nov 13, 2024
EPS Beat/Miss
—
Price Before
$0.31
Price After
$0.32
Q3 FY2024+0.00%
Report Date
Sep 20, 2024
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.23
Beat Rate0 / 8 quarters
Largest Move+17.86% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INBP ends December
Integrated BioPharma, Inc. (INBP) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.03 (in line with the analyst consensus of —). The next INBP earnings date is expected around September 1, 2026.
Each quarter, investors track INBP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INBP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INBP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INBP earnings · 4 questionsIntegrated BioPharma, Inc.'s next earnings report is expected around September 1, 2026. INBP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INBP historically reports after market close (AMC).
INBP earnings datewhen is INBP earningsINBP next earnings datewhen does INBP report earningsINBP earnings calendar
▸ Source: FMP · Integrated BioPharma, Inc. SEC filings · US GAAP · Integrated BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026